RXPA 380 

RXPA 380 is a C-terminal specific angiotensin-converting enzyme (ACE) inhibitor with a K_i of 3 nM. RXPA 380 inhibits C-domain mutants of human recombinant ACE with an IC₅₀ of 2.5 nM^[1].

K_i: 3 nM (C-terminal ACE), 10 μM (N-terminal ACE)^[1]
IC₅₀: 2.5 nM (C-domain mutants of human recombinant ACE), 10 μM (N-domain mutants of human recombinant ACE)^[1]

RXPA 380 shows K_i(app) values of 12 nM and 12 μM for the C- and N-domain of mouse somatic ACE^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RXPA 380 (0.9-30 mg/kg; i.v.; once) inhibits ACE activity in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

617.63

C₃₃H₃₆N₃O₇P

564479-79-4

O=C(O)[C@H](CC1=CNC2=CC=CC=C12)NC(C3C(P([C@@H](NC(OCC4=CC=CC=C4)=O)CC5=CC=CC=C5)(O)=O)CCC3)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Georgiadis D, et al. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. Circ Res. 2003 Jul 25;93(2):148-54.  [Content Brief]